Keyword: Seattle Genetics
Merck's Keytruda has turned up a new head-to-head win against Seattle Genetics’ antibody-drug conjugate Adcetris in refractory cHL.
AZ expects COVID-19 to slow its growth. Health regulators warn of potential drug shortages. Akebia will use a priority review voucher on vadadustat.
Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.
Adcetris' fourth-quarter sales in the U.S. and Canada came in below the Street's expectations and its third-quarter haul, Seattle Genetics reported.
Big biopharmas may still turn to M&As, thanks to their cash power, restructuring plans and a now-or-never mentality, one group of analysts say.
Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
Wednesday, the FDA approved Padcev, a first-of-its kind antibody-drug conjugate. The product targets Nectin-4, a protein on the surface of cells.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
If Seattle Genetics' second-quarter earnings report is any indication, the company's lead product is finally living up to its potential.